Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
The positive topline results from the ORCA-V1 trial, announced earlier this year, will be presented, as well as additional findings.
- The positive topline results from the ORCA-V1 trial, announced earlier this year, will be presented, as well as additional findings.
- Additional analyses showed that vaping abstinence with cytisinicline treatment started by the second week of treatment, with the odds of vaping cessation improving throughout the 12-week treatment period.
- During the Week 12-16 follow-up period, subjects treated with cytisinicline continued to demonstrate 2.0 times higher odds of vaping cessation compared to placebo.
- The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.